Unicycive Therapeutics (UNCY) Non Operating Income (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Non Operating Income data on file, last reported at -$4.4 million in Q1 2026.

• Quarterly Non Operating Income fell 151.24% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.0 million (down 163.56% YoY) and the FY2025 annual result came in at $3.0 million, up 164.22% from the prior year.
• Non Operating Income improved to -$4.4 million in Q1 2026, from -$7.4 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $17.3 million in Q2 2024 to a low of -$12.3 million in Q4 2024.
• A 5-year average of -$1.1 million and a median of -$3000.0 in 2022 frame the typical range for Non Operating Income.
• The widest YoY moves for Non Operating Income: up 53600.0% in 2023, down 49400.0% in 2023.
• Tracing UNCY's Non Operating Income over 5 years: stood at -$3000.0 in 2022, then plunged by 49400.0% to -$1.5 million in 2023, then plunged by 725.86% to -$12.3 million in 2024, then surged by 39.3% to -$7.4 million in 2025, then surged by 41.08% to -$4.4 million in 2026.
• The last three Non Operating Income figures came in at -$4.4 million (Q1 2026), -$7.4 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.